Serum Iodine and Breast Cancer Risk: A Prospective Nested Case-Control Study Stratified for Selenium Levels.


Journal

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608

Informations de publication

Date de publication:
07 2020
Historique:
received: 23 01 2020
revised: 04 03 2020
accepted: 29 04 2020
pubmed: 28 5 2020
medline: 16 9 2021
entrez: 28 5 2020
Statut: ppublish

Résumé

Iodine has been suggested to protect against breast cancer, but there are no epidemiologic studies on individual risk. An interesting finding is that in areas where the exposure to both selenium and iodine are high (e.g., Japan), the risk of breast cancer is lower than in areas where selenium is high and iodine low (e.g., United States), or in areas where both are low (e.g., Northern Europe). The aim of this study was to investigate the association between prediagnostic serum iodine levels and subsequent breast cancer risk, and to investigate if this potential association was modified by selenium levels. The Malmö Diet and Cancer Study provided prediagnostic serum samples and the current analysis included 1,159 breast cancer cases and 1,136 controls. Levels of baseline serum iodine and selenium were analyzed. A logistic regression analysis yielded ORs with 95% confidence intervals adjusted for potential confounders. There was no evidence of an overall association between iodine levels and risk of breast cancer. Among women with high selenium levels (above the median), high iodine levels were associated with a lower risk of breast cancer; the OR for above versus below the median was 0.75 (0.57-0.99). The corresponding OR for women with low selenium was 1.15 (0.87-1.50), and the The combination of high serum iodine levels and high selenium levels was associated with a lower risk of breast cancer. A high iodine and selenium exposure may decrease the risk of breast cancer.

Sections du résumé

BACKGROUND
Iodine has been suggested to protect against breast cancer, but there are no epidemiologic studies on individual risk. An interesting finding is that in areas where the exposure to both selenium and iodine are high (e.g., Japan), the risk of breast cancer is lower than in areas where selenium is high and iodine low (e.g., United States), or in areas where both are low (e.g., Northern Europe). The aim of this study was to investigate the association between prediagnostic serum iodine levels and subsequent breast cancer risk, and to investigate if this potential association was modified by selenium levels.
METHODS
The Malmö Diet and Cancer Study provided prediagnostic serum samples and the current analysis included 1,159 breast cancer cases and 1,136 controls. Levels of baseline serum iodine and selenium were analyzed. A logistic regression analysis yielded ORs with 95% confidence intervals adjusted for potential confounders.
RESULTS
There was no evidence of an overall association between iodine levels and risk of breast cancer. Among women with high selenium levels (above the median), high iodine levels were associated with a lower risk of breast cancer; the OR for above versus below the median was 0.75 (0.57-0.99). The corresponding OR for women with low selenium was 1.15 (0.87-1.50), and the
CONCLUSIONS
The combination of high serum iodine levels and high selenium levels was associated with a lower risk of breast cancer.
IMPACT
A high iodine and selenium exposure may decrease the risk of breast cancer.

Identifiants

pubmed: 32457181
pii: 1055-9965.EPI-20-0122
doi: 10.1158/1055-9965.EPI-20-0122
doi:

Substances chimiques

Iodine 9679TC07X4
Selenium H6241UJ22B

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1335-1340

Informations de copyright

©2020 American Association for Cancer Research.

Auteurs

Jonas Manjer (J)

Department of Surgery, Skåne University Hospital Malmö, Lund University, Malmö, Sweden. jonas.manjer@med.lu.se.

Malte Sandsveden (M)

Department of Surgery, Skåne University Hospital Malmö, Lund University, Malmö, Sweden.

Signe Borgquist (S)

Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.
Department of Oncology, Aarhus University Hospital/Aarhus University, Aarhus, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH